Monographie - Ondansetron hydrochloride

Viimeisin päivitys :
28/04/2024

Ondansetron hydrochloride

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Amal	Meksiko
Ansentron	Brasilia
Antivon	Chile, Meksiko
Atossa	Puola
Avessaron	Belgia
Axisetron	Saksa
Bryterol	Ecuador, Kolumbia
Cellondan	Saksa
Chemoset	Marokko
Danac	Meksiko
Danofran	Egypti
Danset	Egypti
Dantron	Etelä-Afrikka, Marokko
Dasentron	Argentiina, Saudi-Arabia
Dismolan	Argentiina, Venezuela
Donset	Intia
Emeset	Intia, Romania, Turkki
Emetron	Puola, Unkari
Emistop	Marokko, Meksiko
Indansen	Meksiko
Nausetron	Etelä-Afrikka
Ondansan	Itävalta
Ondatron	Saksa
Setronon	Kroatia
Vomiz	Etelä-Afrikka
Yatrox	Espanja
Zofer	Turkki
Zofran	Argentiina, Belgia, Ecuador, Egypti, Hollanti, Irlanti, Islanti, Iso-Britannia, Italia, Itävalta, Kanada, Kolumbia, Luxemburg, Malesia, Marokko, Marokko, New Zealand, Norja, Portugali, Puola, Ruotsi, Saksa, Saudi-Arabia, Suomi, Sveitsi, Tanska, Turkki, Unkari, Yhdistyneet arabiemiirikunnat, Yhdysvallat
Zofron	Kreikka
Zontron	Turkki
Zophren	Ranska, Tunisia
Zotrix	Ruotsi

Viitteet : Ondansetron hydrochloride

	Tyyppi	Julkaisu
3	Lehti	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
6	Lehti	Trissel LA, Xu QA, Martinez JF, Fox JL. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. Am J Hosp Pharm 1994 ; 51: 2138-2142.
16	Lehti	Chung KC, Moon YSK, Chin A, Ulrich WU, Gill MA. Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1554-1556.
18	Lehti	Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA. Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 391-394.
23	Lehti	Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1065-1068.
25	Lehti	McGuire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1410-1414.
26	Lehti	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
30	Lehti	Hagan RL, Mallett MS, Fox JL. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. Am J Health-Syst Pharm 1996 ; 53: 1431-1435.
36	Lehti	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
47	Lehti	Burm JP, Jhee SS, Chin A, Moon YSK. Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration. Am J Hosp Pharm 1994 ; 51: 1201-1204.
50	Lehti	Fleming RA, Olsen DJ, Savage PD, Fox JL. Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. Am J Health-Syst Pharm 1995 ; 52: 514-516.
52	Lehti	Kirkham JC, Rutherford ET, Cumingham GN, Daneshmand KA, Falls AL. Stability of ondansetron hydrochloride in a total parenteral nutrient admixture. Am J Health-Syst Pharm 1995 ; 52: 1557-1558.
53	Lehti	Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
59	Lehti	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Lehti	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Lehti	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Lehti	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Lehti	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Lehti	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
113	Lehti	Jhee SS, Jeong EW, Chin A, Inagaki K, Fox JL, Gill MA. Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C. Am J Hosp Pharm 1993 ; 50: 1918-1920.
132	Lehti	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	Lehti	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	Lehti	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
179	Lehti	Stiles ML, Allen LV Jr, Fox JL. Stability of ondansetron hydrochloride in portable infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 1471-1473.
183	Lehti	Bosso JA, Prince RA, Fox JL. Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C. Am J Hosp Pharm 1992 ; 49: 2223-2225.
184	Lehti	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Lehti	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Lehti	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Lehti	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Lehti	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
266	Lehti	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299	Lehti	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	Lehti	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Lehti	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
332	Lehti	Xu QA, Trissel LA, Fox JL. Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration. Ann Pharmacotherapy 1995 ; 29: 1106-1109.
333	Lehti	Graham CL, Dukes GE, Kao CF, Bertch JM, Hak LJ. Stability of ondansetron in large-volume parenteral solutions. Ann Pharmacotherapy 1992 ; 26: 768-771.
334	Lehti	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Lehti	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Lehti	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
815	Lehti	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905	Lehti	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
915	Lehti	Casto DT. Stability of ondansetron stored in polypropylene syringes. Ann Pharmacotherapy 1994 ; 28: 712-714.
917	Lehti	Blaise N, Vigneron J, Perrin A, Noirez V, Hoffman MA, Hoffman M. Stability of refrigerated and frozen solutions of ondansetron hydrochloride. EJHP 1994 ; 4: 12-13.
921	Lehti	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
969	Lehti	Jarosinski PF, Hirschfeld S. Precipitation of ondansetron in alkaline solutions. N Engl J Med 1991 ; 325: 1315-1316.
979	Lehti	D'Arcy PF. In vitro compatibility of granisetron with selected alkaline drugs. Int Pharm J 1995 ; 9: 57.
992	Lehti	Beijnen JH, Koks CHW. Visual compatibility of ondansetron and dexamethasone. Ann Pharmacotherapy 1991 ; 25: 869.
1026	Lehti	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1396	Lehti	Hauser AR, Trissel LA, Martinez JF. Ondansetron compatible with sodium acetate. J Clin Oncol 1993 ; 11: 197.
1410	Lehti	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Lehti	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Lehti	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Lehti	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Lehti	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Lehti	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1699	Lehti	Plaas S, Heck C, Kubrich M. Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin. Krankenhauspharmazie 2000 ; 21: 107-109.
1712	Lehti	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1721	Lehti	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Lehti	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Lehti	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Lehti	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1868	Lehti	Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1925	Lehti	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Lehti	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2002	Lehti	Abanmy NO, Zaghloul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2012	Lehti	Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. Am J Health-Syst Pharm 2005 ; 62: 2001-2005.
2108	Lehti	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2202	Lehti	Acin Lazaro MP, bono Arino C, martinez Bazan R, manzanares Marin I, Faci Bouthelier A, Velamazan Blocona MJ, Facorro Gaspar E, Estabilidad de parecoxib en dilucion con ostros farmacos y administrado en perfusion continua IV para el control del dolor postoperatorio. Investig Clin Farm 2005 ; 2, 4: 195-203.
2233	Lehti	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2261	Lehti	Fernandez C, Pelloquin A, Berthoume M, Bellanger A, Farinotti R. Stabilité et compatibilité de l'association ondansétron-méthylprednisolone en solution. Can J Hosp Pharm 2008 ; 61, 3: 191-195.
2262	Lehti	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Lehti	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2328	Laboratorio	Sugammadex (Bridion®) – Résumé des caractéristiques du produits Organon 2009
2841	Lehti	Gonzalves Navaro M, Carril Aviles M, Borras Almenar C, Romero Crespo I, Jimenez Torres NV. Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%. Atencion Pharmaceutica 2009 ; 11, 3: 161-166.
3012	Lehti	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3174	Lehti	Rolin C, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM. Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration. Ann Pharmacotherapy 2011 ; 45: 130-131.
3249	Lehti	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Lehti	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	Lehti	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3459	Lehti	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3474	Laboratorio	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3571	Lehti	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3574	Laboratorio	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3595	Laboratorio	Aciclovir - Summary of Product Characteristics Hospira 2009
3728	Lehti	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791	Ilmoitus	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Lehti	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Ilmoitus	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Ilmoitus	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Ilmoitus	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3925	Lehti	Simar J, Godet M, Hecq J.-D, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L. Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C. Ann Pharm Fr 2016 ; 75, 1 : 30-39.
3948	Lehti	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3964	Lehti	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	Lehti	Staven V, Herra I, Wang S, Grönlie I,Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3976	Lehti	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3981	Lehti	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166
4036	Lehti	Estan-Cerezo G, Matoses-Chirivella C, Soriano-Iriga L, Murcia-Lopez A.C, Rodrguez-Lucena F.J, Navarro-Ruiz A. Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. EJHP 2017 ;25,4: 200-203.
4055	Lehti	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4082	Lehti	Espinosa-Bosch M, Sanchez-Rojas F, Bosche-Ojeda C. Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures. EJHP 2018 ; 25, e2
4116	Lehti	Chen F, Zhu J, Li B, Yuan F, Wang K. Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems. Drug Design Dev Ther 2016 ;10:1869-1875
4145	Lehti	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Lehti	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Lehti	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4429	Lehti	Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H. Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration. Medicine 2016 ; 95:25(e3824)
4433	Lehti	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4479	Lehti	Closset M, Goderniaux N, Colsoul M-L, Soumoy L, Bihin B, Jamart J, Odou P, Hecq J-D, galanti L. Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5 +/- 3°C. J Oncol Pharm Practice 2020 ;27,6:1328-1332
4507	Lehti	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4521	Lehti	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Lehti	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4579	Lehti	Tomczak S, Radwan V, Jelinska A, Stawny M. Application of the HPLC Method in Parenteral Nutrition Assessment: Stability Studies of Ondansetron Processes 2021 , 9, 453.
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4666	Lehti	Lee C.H, Kim A.R, Lee M.K, Oh J.S, Lee D.K, Choi S.S. Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron. J Anal Sci Tech 2020 ; 11: 32.
4742	Lehti	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4776	Lehti	Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A. Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures. Pharmaceutics 2023 ; 15: 2143.

Mentions Légales